Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

25 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Long-term course of ambulatory patients with COVID-19 initially treated with enoxaparin vs no anticoagulation: final analysis of the OVID (enoxaparin for outpatients with COVID-19) randomized trial.
Fumagalli RM, Voci D, Bikdeli B, Bingisser R, Colucci G, Forgo G, Gerardi T, Gerber B, Grigorean A, Klok FA, Righini M, Robert-Ebadi H, Stortecky S, Ulrich S, Wolf S, Wyss D, Hobohm L, Kucher N, Barco S; OVID investigators. Fumagalli RM, et al. Among authors: voci d. Res Pract Thromb Haemost. 2024 Jul 26;8(5):102534. doi: 10.1016/j.rpth.2024.102534. eCollection 2024 Jul. Res Pract Thromb Haemost. 2024. PMID: 39252826 Free PMC article.
The TOPOS study.
Sebastian T, Barco S, Voci D, Lichtenberg M, Schlager O, Jalaie H, de Graaf R, Erbel C, Massmann A, Schindewolf M, Spirk D. Sebastian T, et al. Among authors: voci d. Vasa. 2024 May;53(3):217-224. doi: 10.1024/0301-1526/a001118. Epub 2024 Mar 25. Vasa. 2024. PMID: 38525891
Enoxaparin for symptomatic COVID-19 managed in the ambulatory setting: An individual patient level analysis of the OVID and ETHIC trials.
Barco S, Virdone S, Götschi A, Ageno W, Arcelus JI, Bingisser R, Colucci G, Cools F, Duerschmied D, Gibbs H, Fumagalli RM, Gerber B, Haas S, Himmelreich JCL, Hobbs R, Hobohm L, Jacobson B, Kayani G, Lopes RD, MacCallum P, Micieli E, Righini M, Robert-Ebadi H, Rocha AT, Rosemann T, Sawhney J, Schellong S, Sebastian T, Spirk D, Stortecky S, Turpie AGG, Voci D, Kucher N, Pieper K, Held U, Kakkar AK; OVID and ETHIC Investigators. Barco S, et al. Among authors: voci d. Thromb Res. 2023 Oct;230:27-32. doi: 10.1016/j.thromres.2023.08.009. Epub 2023 Aug 18. Thromb Res. 2023. PMID: 37625200 Free article.
Percutaneous large-bore aspiration embolectomy with veno-arterial extracorporal membrane oxygenation support or standby in patients with high-risk pulmonary embolism and contraindications to thrombolysis: a preliminary single centre experience.
Kucher N, Ouda A, Voci D, Barco S, Micieli E, Münger M, Pleming W, Grigorean A, Sromicki J, Schmiady MO, Holy EW. Kucher N, et al. Among authors: voci d. Eur Heart J Acute Cardiovasc Care. 2023 Apr 17;12(4):232-236. doi: 10.1093/ehjacc/zuad014. Eur Heart J Acute Cardiovasc Care. 2023. PMID: 36825861
Enoxaparin for outpatients with COVID-19: 90-day results from the randomised, open-label, parallel-group, multinational, phase III OVID trial.
Voci D, Götschi A, Held U, Bingisser R, Colucci G, Duerschmied D, Fumagalli RM, Gerber B, Hasse B, Keller DI, Konstantinides SV, Mach F, Rampini SK, Righini M, Robert-Ebadi H, Rosemann T, Roth-Zetzsche S, Sebastian T, Simon NR, Spirk D, Stortecky S, Vaisnora L, Kucher N, Barco S; OVID investigators. Voci D, et al. Thromb Res. 2023 Jan;221:157-163. doi: 10.1016/j.thromres.2022.10.021. Epub 2022 Nov 12. Thromb Res. 2023. PMID: 36396519 Free PMC article. Clinical Trial.
25 results